This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Oct. 30, 2012


FDA: Problems identified at New England Compounding Center facility
Medical News Today    Share   Share on FacebookTwitterShare on LinkedinE-mail article
The New England Compounding Center facility has problems maintaining its clean rooms, the Food and Drug Administration informed as it released a copy of the FDA Form 483 to the NECC. The FDA says it listed a number of "observations," including contaminated products. FDA inspectors visited NECC for a total of seven recent days from Oct. 1-26 after the company had recalled a steroid medication. MORE

Related: Pharmacy in meningitis deaths found mold in January (Bloomberg Businessweek)

 Area and Association News

Tamper-resistant prescription pads
AzPA    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The purpose of this memo is to provide guidance on the required use of Tamper Resistant Prescription Pads beginning Nov. 1. AHCCCS and its contractors were waived from this requirement by The Centers for Medicare and Medicaid Services through Oct. 31. However, CMS has not authorized continuation of the waiver exemption for the AHCCCS Program. Therefore, effective Nov. 1, AHCCCS and its Contractors are required to comply with the tamper resistant prescription pad requirement. More


A safe and convenient compliance package to help your patients take their daily medications, wherever they may be.

MediCase requires no expansive heat sealing equipment and it is easily and quickly assembled in your pharmacy to the patient's specific needs.

For more information on Medicase or our other medication compliance products, visit or contact
Diane LaTourelle:

Shop and support AzPA
AzPA    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The next time you shop on, visit the AzPA website first and click on the portal on the home page. When you enter through the AzPA website, a portion of your total purchases will come back to AzPA. Bookmark this link.

Holiday shopping is upon us
AzPA    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Remember to purchase your gift cards through AzPA and support pharmacy education in Arizona. Learn more.

The #1 Selling Brain Health Supplement in Drug Stores Nationally.
Healthier Brain • Sharper Mind • Protect Memories
As we age we lose calcium-binding proteins that protect our brain cells. This protein loss affects our ability to learn, retain memories, think and concentrate.* Prevagen® (apoaequorin) replaces these proteins in the body and helps protect our cells during this natural process of aging.* Over the counter, visit:

Not an AzPA member? Join today
AzPA    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Not an AzPA member? Join the only statewide association representing all pharmacy professionals in all pharmacy practice settings. With over 1,500 members, we are a leading association of pharmacists spreading the news and events of our industry. More

Don't forget to vote!
Share   Share on FacebookTwitterShare on LinkedinE-mail article
Nov. 6 is election day. Don't forget to vote!

 Pharmacy Updates

Quality interactions with pharmacists key to patient satisfaction
Pharmacy Times    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Pharmacist expertise and quality interactions are key markers for determining patient satisfaction and commitment, according to the results of a study published in the September edition of Patient Preference and Adherence. The researchers note that their findings suggest that a patient's sense of their pharmacist’s knowledge level is a prime factor in determining whether they will continue to use the pharmacy, although a level of trust and patient satisfaction must also be cultivated. More

Report faults states' oversight of specialty pharmacies
The Washington Post    Share    Share on FacebookTwitterShare on LinkedinE-mail article
State boards have failed to adequately regulate the safety of practices at specialty pharmacies like the one at the center of the deadly fungal meningitis outbreak, according to a congressional report soon to be released. The report by Rep. Edward J. Markey, D-Mass., looked at enforcement actions against compounding pharmacies in all 50 states and found that only six states had records of taking action. The information was based on what was available on websites and through follow-up telephone calls. More

Rare-disease drugs to receive consideration on par with serious-disease drugs
American Society of Health-System Pharmacists    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In rewriting the statute on fast-track drug products earlier this year, Congress made a point of stating that new drugs addressing the "unmet medical needs" of patients with rare diseases or conditions deserve the special considerations afforded medications for serious or life-threatening conditions. Those special considerations, say industry insiders, should benefit the numerous small populations of patients who have rare diseases. More

2nd compounding pharmacy shut down in Massachusetts
HealthDay News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Massachusetts officials have closed a second compounding pharmacy after a snap inspection revealed conditions that might threaten the sterility of its products. According to The New York Times, Waltham, Mass.-based Infusion Resource voluntarily surrendered its license over the weekend after inspectors found "significant issues with the environment in which medications were being compounded," Dr. Madeleine Biondolillo, director of the Bureau of Health Care Safety and Quality at the Massachusetts Public Health Department, said at a press briefing. More

 In the News

CDC panel expands Tdap vaccine in pregnancy recommendation
Medscape News (free subscription)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recently voted to expand the recommendation for the tetanus, diphtheria and acellular pertussis vaccine during pregnancy to encompass all pregnant women regardless of vaccination history, including repeat vaccinations in subsequent pregnancies. More

Dietary and herbal supplements could interfere with prescription drugs
Medical News Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Certain herb and dietary supplements can produce potentially dangerous drug interference, especially among people taking medication for cardiovascular or nervous system issues. These findings are part of an extensive new research review published in the International Journal of Clinical Practice. More

New OTC inhaler on store shelves
Pharmacy Times    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Nephron Pharmaceuticals has launched an OTC asthma inhaler intended to replace Armstrong Pharmaceuticals' Primatene Mist, which was removed from pharmacy shelves in December 2011 because it used chlorofluorocarbon propellants, which deplete the ozone layer. The introduction of the new OTC inhaler came the month after Armstrong Pharmaceuticals announced a campaign to bring Primatene Mist back to the OTC market during a House of Representatives Energy and Commerce Committee Energy and Power subcommittee hearing. At the time, the company estimated that it had 1 million Primatene Mist inhalers in storage that will expire in August 2013. More

Adult Stem Cell Therapy Breakthrough
Contribute to a breakthrough research project to improve the lives of those suffering from disability and illness associated with aging and receive a free bottle of Stem Cell 100.

JRS Pharma
Powdered cellulose is used as an economic and inert diluent in tableting and capsule filling. Especially in wet granulation it works synergistically with other economic excipients such as starch or lactose. Combined with these, ARBOCEL® improves tablet hardness and disintegration time.

Noveon AA-1 Polycarbophil, USP is a high molecular weight acrylic acid polymer crosslinked with divinyl glycol. It provides excellent bioadhesive properties and has been used extensively to enhance the delivery of active ingredients to various mucous membranes.

 FDA News

Omacetaxine mepesuccinate approved for CML
American Society of Health-System Pharmacists    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The FDA recently approved the tyrosine kinase inhibitor omacetaxine mepesuccinate for the second-line treatment of chronic myelogenous leukemia in adults. The drug is indicated for use in adults with chronic or accelerated phase CML who did not tolerate other therapy or whose illness did not respond to past treatment with two or more tyrosine kinase inhibitors. More

FDA adds 8 drugs to watch list
Medscape News (free subscription)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The Food and Drug Administration has added eight drugs to its list of products to monitor because of possible signs of serious risks or new safety information. The drugs treat conditions that include cancer, epilepsy, hypertension and malaria. More

FDA grants Bayer's Stivarga priority review for GIST treatment
Dow Jones Newswires via NASDAQ    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Bayer AG said the Food and Drug Administration has granted the German pharmaceutical company's Stivarga tablets priority review for the treatment of patients with gastrointestinal stromal tumors. More

FDA: Don't tighten Vicodin regulation
Medpage Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Hydrocodone-containing combination products, such as hydrocodone/acetaminophen, should be kept as Schedule III controlled substances and not be subject to tighter regulations to prevent abuse, the FDA recently recommended. There's insufficient evidence to support the Drug Enforcement Administration's finding that hydrocodone-containing products have a similar abuse potential as Schedule II drugs and should be regulated as such, the FDA said in briefing documents released ahead of a public meeting on the issue. More

AzPA Pharmacy Flash
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Danielle Wegert, Content Editor, 469.420.2696   
Contribute news

This edition of the AzPA Pharmacy Flash was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
Oct. 30, 2012
Oct. 23, 2012
Oct. 16, 2012
Oct. 9, 2012

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063